| HOME >> BIOLOGY >> TECHNOLOGY |
"Martek's policy is to vigorously defend its patent portfolio and these rulings demonstrate the value of this approach," said Steve Dubin, CEO of Martek Biosciences. "Martek's strategy continues to be to develop multiple layers of patent protection. Today our patent portfolio protecting our products and ideas includes more than 700 granted patents and pending applications worldwide."
Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of omega-3 DHA products that promote health and wellness through every stage of life. The Company produces life'sDHA(TM), a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, infant formula and supplements, and life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit www.martek.com.
Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.
Contact:
Cassie France-Kelly
Public Relations, Martek
(443) 542-2116
media@martek.com
Kyle Stults
Investor Relations, Ma
'/>"/>
| SOURCE Martek Biosciences Corporation Copyright©2009 PR Newswire. All rights reserved |